WX

[BigSully1]

August '06 IPO

WuXi PharmaTech (Cayman) Inc.
288 FuTe ZhongLu
Waigaoqiao Free Trade Zone
Shanghai,  200131
China - Map
Phone: 86 21 5046 1111
Fax: 86 21 5046 1000
Web Site: http://www.wuxipharmatech.com

DETAILS   
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Major
Full Time Employees: 1,843


BUSINESS SUMMARY   
WuXi PharmaTech (Cayman), Inc., through its subsidiaries, operates as a pharmaceutical and biotechnology research and development outsourcing company in the People's Republic of China. It provides a portfolio of laboratory and manufacturing services in the drug discovery and development process to pharmaceutical and biotechnology companies. The company's services include discovery chemistry, such as lead generation, lead optimization, and synthetic chemistry; pharmaceutical development comprising formulation development for new chemical entities; and analytical services, including support of its laboratory and manufacturing services, as well as external services offered to customers. Its services also comprise service biology, such as assay development and compound screening; and drug metabolism and pharmacokinetic services, which involves in the analysis of how drug candidates act in the body over time, in vitro and in vivo absorption, disposition, metabolism and excretion, profiling, and metabolite identification. In addition, WuXi PharmaTech's services include process development, such as process research and process optimization services to assist customers to manufacture their drug candidates; and manufacturing of advanced intermediates, which are drug materials prior to refinement into active pharmaceutical ingredients. The company was founded in 2001 and is headquartered in Shanghai, the People's Republic of China.

[BigSully1]

WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Wednesday March 12, 4:30 pm ET 
Full Year Net Revenues up 93.3%; Full Year Net Income up 283.0%


SHANGHAI, China, March 12 /Xinhua-PRNewswire-FirstCall/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX - News), the leading global pharmaceutical, biotechnology and medical device R&D outsourcing company headquartered in Shanghai, China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2007.

    Fourth Quarter 2007 Highlights:

    Compared to the fourth quarter 2006 results,

    -- Total net revenues increased 62.4% to $37.1 million.
    -- Net income increased 205.7% to $12.1 million.
    -- Non-GAAP net income increased 156.7% to $16.6 million.
    -- Diluted earnings per American Depositary Share ("ADS") were $0.17.
       Diluted earnings per ADS excluding share-based compensation expenses
       (non-GAAP) were $0.23.

    Full Year 2007 Highlights:

    Compared to full year 2006 results,

    -- Total net revenues increased 93.3% to $135.2 million.
    -- Net income increased 283.0% to $33.9 million.
    -- Non-GAAP net income increased 158.5% to $44.6 million.
    -- Diluted earnings per ADS were $0.42.  Diluted earnings per ADS
       excluding share-based compensation expenses (non-GAAP) were $0.59.

Commenting on the fourth quarter and full year results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech said, "2007 was an historic year for WuXi, marked by a number of key strategic and tactical milestones. Riding on the rising wave of demand for pharmaceutical and biotechnology R&D outsourcing services, our business experienced phenomenal growth, with revenues for the year at $135 million, up 93% from 2006, attributable to a strong performance across both our laboratory services and research manufacturing segments. We continued to expand our customer base from 70 in 2006 to 80 in 2007, a testimony to our operational excellence and service creed 'We Are Determined to Serve You Better.'

"We remain focused on our goal to transform the drug R&D model globally. An important milestone towards reaching that goal was our recent acquisition of US-based AppTec Laboratory Services Inc., providing us with new capabilities in biologics and medical device testing and manufacturing as well as an expanded geographic footprint. Our integration efforts are ongoing, and by offering a broader range of complementary capabilities across the globe, we are well positioned to drive long-term growth and create value for our customers and shareholders."

Fourth Quarter and Full Year 2007 Unaudited Financial Results

Net Revenues. Net revenues increased 62.4% to $37.1 million in the fourth quarter 2007 from $22.8 million for the fourth quarter 2006. Net revenues from laboratory services increased 33.1% to $28.8 million in the fourth quarter 2007 from $21.7 million in the fourth quarter 2006. The increase was primarily driven by continued strong growth across our core services including discovery chemistry, process research and bioanalytical services. Net revenues from research manufacturing increased by 603.9% to $8.3 million in the fourth quarter 2007 from $1.1 million in the fourth quarter 2006, primarily attributable to an increase in the number and scope of projects.

Net revenues for the full year 2007 increased 93.3% to $135.2 million from $69.9 million in 2006. Laboratory services revenues grew 71.3% to $102.4 million while research manufacturing revenues increased 222.9% to $32.8 million. The growth in net revenues for the full year 2007 is attributable to an increase in business volume for both laboratory services and research manufacturing. Our ongoing commitment to high quality customer service resulted in a doubling of revenues from our top ten customers over the full year 2006.

Gross margins. Overall gross margin was 42.9% in the fourth quarter 2007, down from 56.0% in the fourth quarter 2006 mainly due to the appreciation of RMB across our cost lines and higher bonus incentive payments to our scientific staff over the same period last year.

Gross margins for the full year 2007 were 46.5%, compared to 49.1% for 2006. The decrease is primarily due to the appreciation of RMB across our cost lines and investment in new services such as formulation and toxicology during the year, offset by increased gross margins for our research manufacturing from achieved economies of scale and increased number and scope of research manufacturing projects.

Operating Expenses. Operating expenses decreased 23.7% to $6.6 million in the fourth quarter 2007 from $8.6 million in the fourth quarter 2006 due to bonuses allocated to scientists. Operating expenses as a percentage of total net revenues decreased to 17.7% in the fourth quarter 2007 from 37.7% over the same period last year.

For the full year 2007, operating expenses grew 35.1% to $32.7 million from $24.2 million in 2006. Operating expenses as a percentage of total net revenues in 2007 declined to 24.2% in 2007 from 34.6% in 2006 due to economies of scale.

Net Income. Net income increased by 205.7% to $12.1 million for the fourth quarter 2007 from $4.0 million for the fourth quarter 2006. Net profit margin increased to 32.7% in the fourth quarter 2007 from 17.4% in the fourth quarter 2006. Non-GAAP net income, excluding share-based compensation expenses for the fourth quarter 2007, grew by 156.7% to $16.6 million, compared to the non-GAAP net income of $6.5 million from the fourth quarter 2006. Diluted earnings per ADS were $0.17 and diluted earnings per ADS excluding share-based compensation expenses (non-GAAP) were $0.23 for the fourth quarter 2007.

Net income for the full year 2007 increased by 283.0% to $33.9 million, compared to $8.9 million in 2006. Net profit margin for the year increased to 25.1% from 12.7% in 2006. Non-GAAP net income excluding share-based compensation expenses for the full year 2007 grew by 158.5% to $44.6 million, compared to the non-GAAP net income of $17.3 million from the full year 2006. Diluted earnings per ADS for 2007 were $0.42 and diluted earnings per ADS excluding share-based compensation expenses (non-GAAP) were $0.59 for 2007.

2007 Business Updates

Laboratory services -- Our new offerings in toxicology and formulation services since late 2007 have been well received by our customers. We have already received contracts and anticipate seeing gradual revenue growth from these services.

R&D Facilities -- Total square footage of our laboratory facilities increased 326,200 square feet in 2007.

Jinshan Facility -- Construction of the Jinshan expanded facility is on schedule. We anticipate the facility will be ready for production in the second half of 2008.

Suzhou Facility -- Construction on our GLP (Good Laboratory Practice) facility based in Suzhou, China, which began in the third quarter 2007, remains on track. We continue to expect the facility to come on line in 2009.

Progress on AppTec Integration

The acquisition of AppTec Laboratory Services is focused on driving revenue synergies and complementing our existing chemistry-based services with manufacturing and testing services for biologics and medical device clients, along with providing us with a significant US operational footprint.

The acquisition was completed on January 31, 2008. We continue to make progress on integration activities.

Management -- Retaining key AppTec management is one of our primary goals. All of the key senior management members identified prior to the completion of the acquisition have decided to stay and signed employment agreements. The retention of key executives provides continuity of operations and services to AppTec's existing client base and will help expedite the integration of our complementary service lines.

2008 Guidance

We estimate that our 2008 consolidated revenues will range from $280 million to $300 million.

Conference Call

Following the earnings announcement, WuXi PharmaTech's senior management will host a conference call at 9:00 am (Eastern) / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, March 13, 2008 to discuss its fourth quarter and full year 2007 financial results and recent business activities. The conference call may be accessed by calling (US) +1-888-596-2633/ (UK) +0808-101-1402 / (HK) +800-965-503/ (China, Northern Region) +10-800-714-0970/ (China, Southern Region) +10-800-140-0945. A telephone replay will be available shortly after the call until April 12, 2008 at (US) +1-888-203-1112/ (UK) +0808-101-1153 / (HK) +800-901-108 / (China, Northern Region) +1-719-457- 0820/ (China, Southern Region) +10-800-140-1178, Passcode: 2224172.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .

About WuXi PharmaTech

WuXi PharmaTech, headquartered in Shanghai, China, is the leading global pharmaceutical, biotechnology and medical device R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory, research manufacturing, biologics testing and manufacturing services throughout the drug and medical device research and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device research and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. For more information, please visit: http://www.wuxipharmatech.com .

Use of Non-GAAP Financial Measures

We have provided the fourth quarter and full year of 2006 and 2007 net income and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. We expect to provide net income and earnings per ADS on a non-GAAP basis using a consistent method on a quarterly basis going forward.

You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, the acceptance of and revenues generating from new toxicology and formulation services, the timing of opening facilities in Jinshan and Suzhou, and our integration of AppTec Laboratory Services, including creating a unified global operation, retaining key AppTec management, organizing our sales and marketing teams, reorganizing our service lines, and realizing benefits from the acquisition generally. These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among the factors that could cause our actual results to differ from what we currently anticipate may include our limited operating history; failure to retain key personnel; effective integration of products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our prospectus filed with the Securities and Exchange Commission on August 9, 2007, and is available on the Securities and Exchange Commission's website at http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 11 of our prospectus. Our actual results of operations for the fourth quarter and full year of 2007 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.




                        WUXI PHARMATECH (CAYMAN) INC.
                    UNAUDITED CONSOLIDATED BALANCE SHEETS
             (in thousands of US Dollars, except ordinary share,
                           ADS and par value data)

                                                  December 31,    December 31,
                                                       2007            2006

    Assets:
    Current assets:
      Cash and cash equivalents                      213,585           9,683
      Restricted cash                                  5,526           2,067
      Accounts receivables, net                       18,199          12,589
      Inventories                                     13,352           9,617
      Prepaid expenses and other current assets       11,215           2,696
         Total current assets                        261,877          36,652
    Non-current assets:
      Property, plant and equipment, net              73,635          42,776
      Intangible assets, net                             921             628
      Land use rights, net                             5,160           4,643
      Other non-current assets                         2,182             992
         Total non-current assets                     81,898          49,039

         Total assets                                343,775          85,691

    Liabilities, mezzanine equity and
     shareholders' equity (deficit):
    Current liabilities:
      Short-term bank borrowings, current                 --           9,604
      Accounts payable                                 7,217           9,259
      Accrued expenses                                12,279           5,012
      Deferred revenue                                19,706           2,619
      Advanced subsidies                               1,077             329
      Other taxes payable                              4,060           2,343
      Other current liabilities                        1,233           1,428
         Total current liabilities                    45,572          30,594
    Non-current liabilities:
      Long-term debt, excluding current portion        4,107           5,763
      Advanced subsidies                               1,529           1,027
      Convertible notes                               40,988              --
      Deferred tax liabilities                           181             129
         Total non-current liabilities                46,805           6,919

         Total liabilities                            92,377          37,513

    Mezzanine equity:                                     --          49,106

    Shareholders' equity (deficit):
      Ordinary shares (Note 1), ($0.02 par
      value, 5,002,550,000 authorized
      249,060,000 and 492,226,776 issued
      and outstanding as of December 31,
      2006 and 2007, respectively)                     9,845           4,981
      Additional paid-in capital                     291,020          33,075
      Accumulated deficit                            (57,302)        (40,173)
      Accumulated other comprehensive income           7,835           1,549
      Treasury stock                                      --            (360)
         Total shareholders' equity (deficit)        251,398            (928)

       Total liabilities, mezzanine equity and
        shareholders' equity (deficit)               343,775          85,691

      Note 1: Eight ( ordinary shares are equal to one (1) ADS




                          WUXI PHARMATECH (CAYMAN) INC.
            UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
            (in thousands of US dollars, except ADS and per ADS data)

                                       Three Months Ended      Year Ended
                                          December 31,         December 31,
                                        2007       2006       2007       2006
    Net revenues:
    Laboratory services                28,845     21,674    102,384     59,776
    Research Manufacturing              8,250      1,172     32,821     10,165
    Total net revenues                 37,095     22,846    135,205     69,941

    Cost of revenues:
    Laboratory services               (15,918)    (9,191)   (52,416)   (26,520)
    Research Manufacturing             (5,265)      (852)   (19,931)    (9,109)
    Total cost of revenues            (21,183)   (10,043)   (72,347)   (35,629)

    Gross Profit                       15,912     12,803     62,858     34,312

    Operating expenses:
    Selling and marketing expenses       (650)      (643)    (2,333)    (1,841)
    General and administrative
     expenses                          (5,915)    (7,961)   (30,330)   (22,344)
    Total operating expenses           (6,565)    (8,604)   (32,663)   (24,185)

    Operating income                    9,347      4,199     30,195     10,127

    Other income (expenses), net:
    Other income (expenses), net        1,593        (73)     2,435         35
    Interest income (expenses), net     2,182        (92)     2,771       (912)
    Total other income (expenses), net  3,775       (165)     5,206       (877)

    Income before income taxes         13,122      4,034     35,401      9,250

    Income taxes                         (991)       (66)    (1,498)      (397)

    Net income                         12,131      3,968     33,903      8,853

    Income (loss) attributable to
     holders of ADS:
    Basic                              12,131      2,313     21,655    (35,148)
    Diluted                            12,131      2,313     27,279    (35,148)

    Basic earnings (loss) per ADS        0.20       0.08       0.56      (1.18)
    Diluted earnings (loss) per ADS      0.17       0.07       0.42      (1.18)

    Number of shares used in
     calculation (Note 2):

    Weighted average ADS
     outstanding - basic           61,528,350 28,882,500 38,506,277 29,813,325
    Weighted average ADS
     outstanding - diluted         72,544,322 35,022,194 64,393,436 29,813,325

    Note 2: One (1) ADS equals eight ( ordinary shares



                          WUXI PHARMATECH (CAYMAN) INC.
                       RECONCILIATION OF NON-GAAP TO GAAP
               (in thousands of  US Dollars, except per ADS data)
                                   (Unaudited)

                                     Three Months Ended       Year Ended
                                        December 31,          December 31,
                                     2007       2006        2007       2006

    GAAP net income                 12,131      3,968      33,903      8,853

    Add: Share-based compensation
     expenses                        4,454      2,493      10,715      8,409

    Non-GAAP net income             16,585      6,461      44,618     17,262

    Income (loss) attributable
     to holders of ADS
     (Non-GAAP):
       Basic                        16,585      3,766      31,477    (26,739)
       Diluted                      16,585      3,766      37,994    (26,739)

    Basic earnings (loss) per
     ADS (Non-GAAP)                   0.27       0.13        0.82      (0.90)
    Diluted earnings (loss) per
     ADS (Non-GAAP)                   0.23       0.11        0.59      (0.90)

    Weighted average ADS
     outstanding - basic        61,528,350 28,882,500  38,506,277 29,813,325
    Weighted average ADS
     outstanding - diluted      72,544,322 35,022,194  64,393,436 29,813,325

[BigSully1]

I'm glad I bought lots  below $20.

Only 4 views? I'm wasting my time here.

[buddjas1]

Not wasting your time Sully.  If you got a good runner like this, please let me know on my journal.  I could use the tips!

A break out over the trend line could give you 20% or more.

"In 2008, the company said it expects revenue between $280 million and $300 million, while analysts expect revenue of $237.1 million."

http://seekingalpha.com/article/68528-wuxi-pharmatech-beats-estimates-should-see-upside?source=etrade

Jeffries upgraded with $30 target.

Applaud BSully.

[BigSully1]

Press Release Source: WuXi PharmaTech Inc.


WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
Friday April 4, 12:24 pm ET


SHANGHAI, China, April 4, 2008 /Xinhua-PRNewswire-FirstCall/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX - News; "WuXi PharmaTech"), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has filed a Registration Statement on Form F-1 with the Securities and Exchange Commission for a proposed follow-on and secondary public offering of American Depositary Shares. The securities to be sold in the proposed offering will include shares to be issued and sold by the company as well as shares to be sold by certain shareholders.
---------------------------------------------------------

sold half at $24 the other day. Dumped the rest at $22.25 today on the news. Will look to buy back later.